{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:57:03Z","timestamp":1776275823709,"version":"3.50.1"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HF20C0222"],"award-info":[{"award-number":["HF20C0222"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With the increasing survival rate and overall lifespan of patients with breast cancer, increased mortality due to cardiovascular causes is a notable concern. Anthracyclines, which are commonly used and effective chemotherapeutic agents for breast cancer, are known for their cardiotoxicity. Existing studies vary in their findings owing to heterogeneous factors such as study population and design, underscoring the need for high-quality evidence to comprehensively examine the risk factors for anthracycline-induced cardiotoxicity. This study compared the incidence of cardiovascular disease, all-cause mortality, and their associated risk factors following adjuvant anthracycline therapy as the initial anticancer treatment, utilizing National Health Insurance claims data for a nationwide cohort of patients with breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study cohort comprised patients initially diagnosed with breast cancer between 2011 and 2013 who underwent mastectomy within 6 months of diagnosis and received anticancer therapy within 6 months of surgery. The primary outcomes were composite cardiovascular events and all-cause mortality during a follow-up period of up to 5 years. Secondary outcomes encompassed specific types of cardiovascular events such as congestive heart failure, heart failure and cardiomyopathy, coronary artery disease and cardiac arrest, and stroke. Incidence rates for these outcomes were presented as incidence rate ratios (IRR), and hazard ratios (HR) for individual risk factors were derived using the Cox proportional hazards model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study cohort comprised 9,439 patients with breast cancer in both the anthracycline and non-anthracycline groups. There was no significant association between adjuvant anthracycline therapy and the composite cardiovascular events (adjusted HR 0.911 [95% CI 0.823\u20131.008]). In contrast, all-cause mortality was higher in the anthracycline group (IRR 2.155 [95% CI 1.892\u20132.455]; adjusted HR 2.160 [95% CI 1.882\u20132.480]). Adjuvant trastuzumab was significantly associated with an increased risk of the composite cardiovascular event (adjusted HR 1.256 [1.093\u20131.443]), although no trend was identified concerning adjuvant trastuzumab status in the subgroup analysis. Advanced age and hypertensive comorbidities were risk factors for all outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To prevent cardiovascular event onset in patients with breast cancer undergoing anthracycline-based chemotherapy, thorough monitoring is essential, especially in patients of advanced age, those with comorbid hypertension, and those undergoing trastuzumab treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0335083","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T18:56:26Z","timestamp":1764874586000},"page":"e0335083","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk of cardiovascular disease and death in patients with breast cancer receiving anthracycline-based therapy: A retrospective cohort study"],"prefix":"10.1371","volume":"20","author":[{"given":"Yu-Cheol","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Hyuk","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-5401","authenticated-orcid":true,"given":"Ye-Seul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"5","key":"pone.0335083.ref001","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"KD Miller","year":"2019","journal-title":"CA: A Cancer J Clin"},{"issue":"7","key":"pone.0335083.ref002","first-page":"2175","article-title":"Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer","volume":"22","author":"MA Nicolazzi","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"26","key":"pone.0335083.ref003","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1056\/NEJM200106283442607","article-title":"Side effects of adjuvant treatment of breast cancer","volume":"344","author":"CL Shapiro","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0335083.ref004","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/annonc\/mdq683","article-title":"Long-term toxic effects of adjuvant chemotherapy in breast cancer","volume":"22","author":"HA Jr Azim","year":"2011","journal-title":"Ann Oncol"},{"issue":"5","key":"pone.0335083.ref005","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"DD Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"issue":"6","key":"pone.0335083.ref006","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1517\/14740338.5.6.791","article-title":"Anthracycline cardiotoxicity","volume":"5","author":"RL Jones","year":"2006","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"pone.0335083.ref007","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/1078-0432.CCR-07-1033","article-title":"Cardiac toxicity in breast cancer survivors: review of potential cardiac problems","volume":"14","author":"BRJH Bird","year":"2008","journal-title":"Clin Cancer Res"},{"key":"pone.0335083.ref008","article-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines","author":"G Curigliano","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"pone.0335083.ref009","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2165\/00002018-200831060-00002","article-title":"Cardiotoxicity profile of trastuzumab","volume":"31","author":"SM Ewer","year":"2008","journal-title":"Drug Saf"},{"issue":"25","key":"pone.0335083.ref010","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"MC Pinder","year":"2007","journal-title":"J Clin Oncol"},{"issue":"16","key":"pone.0335083.ref011","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0335083.ref012","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11739-015-1362-x","article-title":"Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer","volume":"11","author":"S Mantarro","year":"2016","journal-title":"Intern Emerg Med"},{"issue":"4","key":"pone.0335083.ref013","first-page":"407","article-title":"Trastuzumab-induced cardiomyopathy","volume":"37","author":"R Barish","year":"2019","journal-title":"Cardiol Clin"},{"issue":"11","key":"pone.0335083.ref014","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"DJ Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0335083.ref015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","article-title":"Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer","volume":"18","author":"L Tarantini","year":"2012","journal-title":"J Card Fail"},{"issue":"9","key":"pone.0335083.ref016","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/annonc\/mdn292","article-title":"Anthracycline-trastuzumab regimens for HER2\/neu-overexpressing breast cancer: current experience and future strategies","volume":"19","author":"D Rayson","year":"2008","journal-title":"Ann Oncol"},{"issue":"6","key":"pone.0335083.ref017","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-oncology: an update on cardiotoxicity of cancer-related treatment","volume":"118","author":"CG Lenneman","year":"2016","journal-title":"Circ Res"},{"issue":"2","key":"pone.0335083.ref018","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.radonc.2011.06.016","article-title":"Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden","volume":"100","author":"P McGale","year":"2011","journal-title":"Radiother Oncol"},{"issue":"25","key":"pone.0335083.ref019","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"MC Pinder","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"pone.0335083.ref020","first-page":"364","article-title":"Adriamycin (doxorubicin) cardiotoxicity: a review","volume":"131","author":"RT Chlebowski","year":"1979","journal-title":"West J Med"},{"issue":"8","key":"pone.0335083.ref021","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical oncology clinical practice guideline","volume":"35","author":"SH Armenian","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0335083.ref022","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"G Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"pone.0335083.ref023","doi-asserted-by":"crossref","first-page":"430","DOI":"10.7326\/0003-4819-94-4-430","article-title":"Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography","volume":"94","author":"JS Gottdiener","year":"1981","journal-title":"Ann Intern Med"},{"issue":"8","key":"pone.0335083.ref024","first-page":"869","article-title":"Chemotherapy-induced cardiotoxicity: detection, prevention, and management","volume":"30","author":"J Truong","year":"2014","journal-title":"Can J Cardiol"},{"issue":"2","key":"pone.0335083.ref025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-019-05303-y","article-title":"HER2+ breast cancer treatment and cardiotoxicity: monitoring and management","volume":"177","author":"G Jerusalem","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"pone.0335083.ref026","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1002\/cam4.3956","article-title":"Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin","volume":"10","author":"M Lee","year":"2021","journal-title":"Cancer Med"},{"issue":"2","key":"pone.0335083.ref027","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2478\/raon-2013-0040","article-title":"Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer","volume":"48","author":"T Marinko","year":"2014","journal-title":"Radiol Oncol"},{"issue":"11","key":"pone.0335083.ref028","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1080\/14740338.2022.2151584","article-title":"Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects","volume":"21","author":"P Di Nardo","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0335083.ref029","first-page":"18","article-title":"Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors","volume":"5","author":"N Bansal","year":"2019","journal-title":"Cardiooncology"},{"issue":"12","key":"pone.0335083.ref030","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity","volume":"112","author":"M Lotrionte","year":"2013","journal-title":"Am J Cardiol"},{"issue":"3","key":"pone.0335083.ref031","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10549-017-4282-9","article-title":"Risk of death from cardiovascular disease following breast cancer: a systematic review","volume":"164","author":"SAM Gernaat","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"pone.0335083.ref032","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast Cancer Treatment: A Review","volume":"321","author":"AG Waks","year":"2019","journal-title":"JAMA"},{"key":"pone.0335083.ref033","article-title":"Risk of lymphedema and death after lymph node dissection with neoadjuvant and adjuvant treatments in patients with breast cancer: an eight-year nationwide cohort study","author":"YS Lee","year":"2023","journal-title":"Healthcare"},{"key":"pone.0335083.ref034","doi-asserted-by":"crossref","first-page":"899782","DOI":"10.3389\/fonc.2022.899782","article-title":"Risk factors for anthracycline-induced cardiotoxicity in breast cancer treatment: a meta-analysis","volume":"12","author":"M Zhang","year":"2022","journal-title":"Front Oncol"},{"issue":"12","key":"pone.0335083.ref035","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1002\/cam4.1886","article-title":"Doxorubicin-induced heart failure in cancer patients: a cohort study based on the Korean national health insurance database","volume":"7","author":"YA Kim","year":"2018","journal-title":"Cancer Med"},{"issue":"1","key":"pone.0335083.ref036","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2021-000094","article-title":"Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness","volume":"1","author":"NR Latimer","year":"2022","journal-title":"BMJ Med"},{"issue":"12","key":"pone.0335083.ref037","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1002\/cncr.21919","article-title":"The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis","volume":"106","author":"RS Punglia","year":"2006","journal-title":"Cancer"},{"issue":"7","key":"pone.0335083.ref038","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/annonc\/mdn756","article-title":"What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?","volume":"20","author":"CH Barrios","year":"2009","journal-title":"Ann Oncol"},{"issue":"21","key":"pone.0335083.ref039","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1056\/NEJMp2407586","article-title":"\u201cTarget Trial Emulation\u201d for observational studies - potential and pitfalls","volume":"391","author":"RA Hubbard","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0335083.ref040","first-page":"655","article-title":"Anthracycline cardiotoxicity in adult cancer patients: JACC: cardioOncology state-of-the-art review","volume":"6","author":"M Camilli","year":"2024","journal-title":"Cardio Oncology"},{"issue":"14","key":"pone.0335083.ref041","first-page":"5078","article-title":"HER-2-targeted therapy: lessons learned and future directions","volume":"9","author":"R Nahta","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"3","key":"pone.0335083.ref042","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study","volume":"13","author":"JL Patnaik","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"5","key":"pone.0335083.ref043","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11739-012-0794-9","article-title":"Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer","volume":"7","author":"G Russo","year":"2012","journal-title":"Intern Emerg Med"},{"issue":"16","key":"pone.0335083.ref044","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer","volume":"347","author":"B Fisher","year":"2002","journal-title":"N Engl J Med"},{"issue":"9804","key":"pone.0335083.ref045","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials","volume":"378","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"pone.0335083.ref046","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrclinonc.2015.171","article-title":"Breast cancer therapy-associated cardiovascular disease","volume":"13","author":"TM Zagar","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"pone.0335083.ref047","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","article-title":"Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis","volume":"49","author":"K Kalam","year":"2013","journal-title":"Eur J Cancer"},{"issue":"7","key":"pone.0335083.ref048","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrclinonc.2015.73","article-title":"Clinical management of breast cancer heterogeneity","volume":"12","author":"D Zardavas","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"pone.0335083.ref049","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of hazard ratios","volume":"21","author":"MA Hern\u00e1n","year":"2010","journal-title":"Epidemiology"},{"issue":"17","key":"pone.0335083.ref050","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1200\/JCO.2015.65.8716","article-title":"Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer","volume":"34","author":"K Reeder-Hayes","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0335083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T18:56:35Z","timestamp":1764874595000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0335083"}},"subtitle":[],"editor":[{"given":"Mohammad Zeeshan","family":"Najm","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0335083","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]}}}